MBX Biosciences, Inc. (MBX) Cash Flow Statement
MBX Biosciences, Inc. (MBX) generated -$82.7M of operating cash flow over the twelve months to 2026-06-30, spent $2.5M on capital expenditure and had free cash flow of -$85.2M, according to EquiReason's reading of its SEC filings.
Source: SEC EDGAR filings · figures as of 2026-06-30 · read by EquiReason
MBXMBX Biosciences, Inc.Follow MBX — free
—
Price chart with a free account
- Market cap
- 2.3B
- P/E TTM
- —
- Dividend yield
- —
- 52-week
- —
- Next earnings
- 5 Nov, in 12 days
| Line | FY2024 Dec 24 | FY2025 Dec 25 | TTM Jun 26 | Trend |
|---|---|---|---|---|
| Operating cash flow | -54.7 | -79.9 | -82.7 | |
| Capital expenditure | 0.9 | 1.9 | -2.5 | |
| Free cash flow | -55.6 | -81.9 | -85.2 | |
| Stock-based compensation | 5.2 | 8.7 | — |
USD millions · SEC XBRL
MBX Biosciences, Inc. — questions
- What is MBX Biosciences, Inc.'s operating cash flow?
- -$82.7M over the twelve months to 2026-06-30.
- How much does MBX Biosciences, Inc. spend on capital expenditure?
- $2.5M over the twelve months to 2026-06-30.
- What is MBX Biosciences, Inc.'s free cash flow?
- -$85.2M over the twelve months to 2026-06-30: operating cash flow minus capital expenditure.
Every figure on this page comes from MBX Biosciences, Inc.'s own SEC filings — see them on SEC EDGAR. Price data is licensed and shown only inside the product.
How these figures are read: methodology · EquiReason.